Corient Private Wealth LLC Buys 11,889 Shares of Stryker Co. (NYSE:SYK)

Corient Private Wealth LLC lifted its stake in Stryker Co. (NYSE:SYK) by 1.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,097,038 shares of the medical technology company’s stock after buying an additional 11,889 shares during the period. Stryker makes up approximately 0.6% of Corient Private Wealth LLC’s investment portfolio, making the stock its 26th biggest position. Corient Private Wealth LLC’s holdings in Stryker were worth $394,990,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. J. W. Coons Advisors LLC boosted its stake in shares of Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after buying an additional 26 shares during the period. Mascoma Wealth Management LLC lifted its stake in Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock worth $53,000 after purchasing an additional 27 shares during the last quarter. Opal Wealth Advisors LLC lifted its stake in Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock worth $654,000 after purchasing an additional 28 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock worth $507,000 after purchasing an additional 28 shares during the last quarter. Finally, Alhambra Investment Management LLC lifted its stake in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after purchasing an additional 29 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SYK. Citigroup restated a “buy” rating and set a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Canaccord Genuity Group upped their price target on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Stock Performance

Shares of Stryker stock opened at $369.96 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $383.04 and a two-hundred day moving average price of $373.48. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a market cap of $141.17 billion, a P/E ratio of 47.68, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.